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Abstract Bartonella henselae is the causative agent of cat
scratch disease in humans, which is recognized as an emerg-
ing zoonotic disease. Ctenocephalides felis is the main vector,
and transmission of B. henselae infection between cats and
humans occurs mainly through infected flea feces. Control of
feline infestation with this arthropod vector therefore provides
an important strategy for the prevention of infection of both
humans and cats. In the present study, a new challenge model
is used to evaluate the efficacy of selamectin (Stronghold®
spot on) in the prevention of B. henselae transmission by
C. felis. In this new challenge model, domestic cats were
infected by direct application of B. henselae-positive fleas.
The fleas used for infestation were infected by feeding on
blood that contained in vitro-cultured B. henselae. The direct
application of the fleas to the animals and the use of different
B. henselae strains ensured a high and consistent challenge.
Two groups of six cats were randomly allocated on pre-
treatment flea counts to either control (untreated cats) or the
selamectin-treated group with one pipette per cat according to
the label instruction. Stronghold (selamectin 6 % spot on
solution) was administered on days 0 and 32. On days 3, 10,
19, 25, and 31, each cat was infested by direct application of
20 fleas that fed on blood inoculated with B. henselae. Poly-
merase chain reaction (PCR) on pooled fleas confirmed that
the fleas were infected. Blood samples were collected from
each cat on days −3 (prior to flea infestation and treatment), 9,
17, 24, 30, 37, and 44 and assayed for B. henselae antibodies
using an indirect immunofluorescence (IFA), for the presence
of bacteria by bacterial culture and for B. henselae DNA
presence by PCR. Cats were also assessed on a daily basis
for general health. There were no abnormal health observations
during the study and none of the animals required concomitant
treatment. None of the cats displayed any clinical signs of
bartonellosis during the study. In the untreated group, all cats
became bacteremic within 17 to 44 days. None of the
selamectin-treated cats became positive during the study. It
was concluded that Stronghold® spot on administered to cats
was efficacious in the prevention of the transmission of
B. henselae by fleas to cats in a high-challenge model.
Keywords Bartonellosis .Bartonella henselae . Selamectin .
New challengemodel . Fleas . Flea control
Introduction
Bartonella henselae is a Gram-negative bacteria distribut-
ed worldwide and is recognized as an emerging zoonotic
agent (Chomel and Kasten 2010). It is mostly known as
the causative agent of cat scratch disease (CSD) in
humans (Chomel et al. 2004). The reservoir is the do-
mestic cat, and the cat flea, Ctenocephalides felis, is
believed to function as a competent vector (Chomel
et al. 1996). Infected cats are usually asymptomatic but
may experience relapsing bacteremia, which can last for
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months or even years (Breitschwerdt and Kordick 1995;
Jacomo et al. 2002). Intradermal inoculation of
B. henselae to kittens is followed by bacteremia, which
usually appears within 1 to 3 weeks and may last for
60 days (Kordick et al. 1995; Abbott et al. 1997). In
some cats, B. henselae seropositivity has been associated
with lymphadenitis, gingivitis, stomatitis, or urological
diseases (Glaus et al. 1997; Breitschwerdt and Kordick
2000). B. henselae has also been considered as a poten-
tial cause of anterior uveitis, myocarditis (Lappin and
Black 1999; Bradbury and Lappin 2010), and endocardi-
tis (Chomel et al. 2003).
In humans, CSD is characterized by a persistent regional
lymphadenopathy, which usually resolves within 2 to
4 months in immunocompetent patients (Boulouis et al.
2005). In immunocompromised individuals (such as those
with AIDS or organ transplant recipients), the infection with
B. henselae can lead to a wide range of life-threatening dis-
eases, such as bacillary angiomatosis or bacillary peliosis
(Boulouis et al. 2005; Breitschwerdt 2008; Klotz et al. 2011).
The prevalence of bacteremia among cats varies from 4 to
70 % depending on the way of life of the cat (domestic or stray
cat), its age, its geographical location, and the degree of flea
infestation (Chomel et al. 1995; Maruyama et al. 2000; Rolain
et al. 2004). More than 50 % of cats are bacteremic to
B. henselae in regions where C. felis is endemic (Heller et al.
1997). The key identified vector of B. henselae transmission
among cats is Ctenocephalides felis (Chomel et al. 1996), and
cats are the natural reservoir for this flea. The transmitted
material seems to be the infected flea feces excreted on the
fur of the flea-infested cat (Foil et al. 1998).B. henselae remains
viable in the environment for at least 3 days (Finkelstein et al.
2002). Bacterial DNA is still detected in the fleas and excreted
feces 12 days after infection (Bouhsira et al. 2013a, b). While
grooming, cats contaminate their mouth and claws with con-
taminated flea dejections which can also be inoculated to
humans by scratching or biting (Zangwill et al. 1993; Eisen
and Gage 2012). Therefore, the best strategy to prevent
bartonellosis relies on the control of flea infestations.
Lately, the use of ectoparasitic treatment as a tool in the
prevention of pathogen transmission has been advocated
(Beugnet and Franc 2012). Therefore, available formulations
against ticks and fleas in cats and dogs need to be tested for
their efficacy in preventing the transmission of arthropod-
borne pathogens such as B. henselae. Two recent studies
indeed demonstrated the efficacy of imidacloprid/moxidectin
and imidacloprid/flumethrin combinations in preventing
B. henselae transmission among cats via natural transfer of
fleas (Bradbury and Lappin 2010; Lappin et al. 2013). In the
present study, a new challenge model using experimentally
infected fleas was used to evaluate the efficacy of selamectin




Animals were handled in strict accordance with good animal
practice as defined by the relevant European standards of
welfare for animals in research. The animal study was per-
formed at the École Nationale Vétérinaire de Toulouse
(ENVT), Toulouse, France, and was reviewed and approved
by the ethic committee of theMidi-Pyrénées region and by the
Zoetis Ethical Review Assessment Committee.
Animals
Twelve healthy specific pathogen-free (SPF) domestic cats
from ENVT, weighing between 3.2 and 5.2 kg and aged
2 years (11 cats) and 4 years (1 cat), were used in this study.
Before inclusion, all cats had been vaccinated against feline
viral rhinotracheitis, feline calicivirus, feline distemper virus,
and rabies virus and were FeLV antigen and FIV antibody
negative. The absence of Bartonella spp. in cat blood was
confirmed by polymerase chain reaction (PCR) and bacterial
cultures (see below); results for serum antibody against
Bartonella spp. were also negative. Cats were flea free and
had not received any ectoparasitic treatments in the 3 months
prior to the study treatment.
Cats were housed in an indoor cattery with natural envi-
ronmental lighting and acclimatized to the study conditions
for 2 months prior to inclusion. Cats were kept by treatment
group in two separate pens. The pen environment was
enriched by shelves, perches, toys, and wooden claw-
sharpening boards. Water and dry cat food appropriate for
the cats’ age were provided ad libitum. The cattery and litter
trays were cleaned daily. Animals were handled and moni-
tored daily for any physiological abnormalities. Once a week,
ocular and gingival mucosae were inspected for signs of
anemia.
Treatment administration
On days 0 and 32, six cats were treated with selamectin
(Stronghold® spot on for cats, 1 pipette administered topical-
ly) according to the manufacturer’s instruction on the ap-
proved European label of the product. The actual dose varied
between 8.7 and 14.1 mg/kg bodyweight. The other six cats
were left untreated and served as an untreated control group.
Bacterial strains and growth conditions
Strains of B. henselae 16S rRNA genotypes I and II isolated
from cats were used. The B. henselae strains were grown on
brain heart infusion (BHI) agar (Difco Laboratories, Detroit,
USA) supplemented with 5 % of fresh rabbit blood in
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humidified atmosphere at 35 °C in 5 % carbon dioxide atmo-
sphere. For flea infection procedures, bacteria were collected
after 5 days growth on BHI agar plates and suspended in
phosphate-buffered saline (PBS) buffer. The bacterial suspen-
sionwas dilutedwith PBS to obtain approximately 2×108 bac-
teria/ml as adjusted by turbidimetry.
Fleas and artificial feeding
The C. felis strain was obtained from a laboratory-reared
colony originating from a wild strain harvested from a cat
and maintained on cats under laboratory conditions since
1990 at ENVT. Prior to use for this study, fleas were
ascertained to be negative for Bartonella spp. infection by
PCR. Canine blood used to feed fleas was obtained from three
healthy 6-year-old beagle dogs correctly vaccinated. Blood
smears and the microhematocrit of the three dogs were
checked before their inclusion in the study, and none of the
dogs showed any abnormalities. The absence of Bartonella
spp. in dog blood was confirmed by PCR. Blood samples
obtained by venipuncture were placed in lithium heparin-
coated Vacutainer tubes (Venosafe®, Laboratoires Terumo
France, Guyancourt, France). Blood functional complement
was deactivated by storing blood samples at room temperature
for 1 h after the blood was drawn and before storage at 4 ° C.
Blood samples were kept at 4 °C for no longer than 24 h.
On days 2, 9, 18, 24, and 30, 500 freshly emerged adult
unfed fleas were placed in a Plexiglas box in contact with a
glass feeder closed at the bottom with a thin Parafilm® mem-
brane (Parafilm® 3M, Pechiney Plastic Packaging, IL, USA).
Fleas had not received any blood meal before the start of the
study. To stimulate the flea to blood feed, a constant temper-
ature of 38.5 °C, mimicking the host’s body temperature, was
maintained by a water jacket circulation system through the
glass feeder. The fleas were fed on 5 ml of blood mixed with
500 μl of B. henselae in suspension in PBS at a concentration
of approximately 2×108 bacteria/ml. After 24 h of feeding,
fleas were removed and identified as having fed successfully
by observation of distension of the abdomen with the naked
eye. The engorged fleas were then divided into 12 batches of
20 fleas each. A 13th batch of 20 fleas was reserved weekly
for B. henselae PCR analysis, in order to check the proper
contamination of fleas with the bacterium. The twelve cats
were infested weekly with 20 engorged fleas on days 3, 10,
19, 25, and 31. Fleas were not removed by combing from cats
until the end of the study.
Sample collection
Blood samples of cats were collected via ante-brachial veni-
puncture by use of a 22-gauge needle on study days −3 (prior
to flea infestation and treatment) 9, 17, 24, 30, 37, and 44.
Blood was distributed into two sterilized, DNA/RNA-free and
EDTA-treated tubes (Venosafe® plastic tubes, Laboratoires
Terumo France, Guyancourt, France) to avoid contaminations
(1 ml dedicated to PCR and 1 ml to bacterial culture) and in
one untreated tube (1 ml blood for serum) (Venosafe® plastic
tubes, Laboratoires Terumo France, Guyancourt, France). The
EDTA blood samples were immediately frozen at −18 °C until
PCR assays and bacterial culture. The untreated tubes were
kept at ambient temperature for 1 h to help the blood clot
before serum preparation. They were then centrifuged at 500 g
at 4 °C for 10 min and stored at −18 °C until determination of
IgG titers against Bartonella spp.
Blood culture for Bartonella
The EDTA tubes were thawed and spun at 1800g for 75min at
room temperature, and the supernatant was discarded. The
pellet was suspended in 250 μl of inoculation medium
(Schneider’s Drosophila medium 1×, L-glutamine, Gibco,
France) and the volume recorded. Then, 250 μl of the suspen-
sion was inoculated onto BHI agar supplemented with 5 %
defibrinized fresh rabbit blood. The remaining suspension was
inoculated onto a second plate. The plates were incubated for
1 month at 35.5 °C with 5 % CO2 in a humid incubator and
checked regularly for bacterial growth. Colonies were identi-
fied to Bartonella by their aspect, time of colony appearance,
and Gram staining. At least one colony per cat/day was
subcultured, harvested, and frozen at −70 °C in 100 % fetal
calf serum. Identification of B. henselae was performed on
subculture of one colony by PCR targeting the citrate synthase
(gltA) gene (Norman et al. 1995).
PCR assays
Two-hundred microliters of EDTA blood was extracted by
Nucleospin Blood Quickpure Macherey Nagel Kit
(Macherey-Nagel, Hoerdt, France). Then, two PCRs were
carried out: a PCR targeting the citrate synthase (gltA) gene
followed by a nested PCR targeting the ITS gene (Rampersad
et al. 2005). A cat blood sample was regarded as positive to
B. henselaeDNAwhen at least one PCR result among the two
performed PCR assays (gltA gene and ITS gene) was positive.
From each batch of fleas used for the weekly infestations of
the cats, a pool of five fleas was extracted by Nucleospin
Tissue Quickpure Macherey Nagel Kit (Macherey-Nagel,
Hoerdt, France) and a PCR targeting the Bartonella gltA gene
was carried out.
Serology/IFA
One of the B. henselae strains used in this assay was passed
from agar-grown cultures into Vero cells. Heavily infected cell
cultures were spotted onto 12-well Teflon-coated slides, incu-
bated 18 h in a CO2 incubator, acetone fixed, and stored
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frozen. B. henselae antibodies were determined after tradition-
al IFA practices. Fluorescein-conjugated goat anti-cat IgG
(Bethyl Lab, Montgomery, USA) was used at the dilution of
1/50 in PBS. Serum samples were diluted in phosphate-
buffered saline solution. Cat sera were screened at a dilution
of 1:64 (cutoff titer). All sera that remained reactive at a titer of




No abnormal health event was observed in any of the cats
throughout the study. Pruritus or hair loss was not observed.
No abnormal behavior, anorexia, weakness, or anemia was
detected, and no clinical signs of bartonellosis were observed
after the start of the flea infestation.
Bartonella spp. PCR assays and blood culture
In the selamectin-treated group, none of the cats became
positive at any time during the study.
In the untreated group, all cats became PCR positive during
the study. The PCR-positive samples from the control cats
were also positive by blood culture. The interval to a positive
PCR assay or culture result ranged from 14 to 41 days of flea
exposure with a median of 21 days. The first amplification of
B. henselaeDNAwas obtained on two cats (cats 5 and 6) after
14 days of exposure to fleas. Bacteremia in these two cats
lasted for at least 4 weeks, the duration of the study. Cats 2, 3,
and 4 had positive PCR and culture results 3 weeks after the
first flea infestation and 1 week after the second infestation.
These three cats were bacteremic for at least 3 weeks. On
study day 44 (41 days after the first flea infestation), the sixth
cat in the negative control group (cat 1) was also bacteremic
and PCR positive. (Fig. 1)
All the pools of fleas tested were PCR positive for the gltA
gene except the pool used before the treatment for the
allocation.
Serology
In the untreated group, five out of the six cats developed
detectable anti-B. henselae IgG titers, with interval to sero-
conversion ranging from 21 to 41 days of the first fleas
exposure. Titers ranged from 1:64 to 1:512, and once positive
titers were detected, cats remained seropositive for the dura-
tion of the study. None of the selamectin-treated cats serocon-
vert during the study. (Fig. 1)
Discussion
Recent studies investigated the efficacy of imidacloprid for-
mulations in preventing the transmission of B. henselae by
fleas in cats (Bradbury and Lappin 2010; Lappin et al. 2013).
In these studies, cats in one group were inoculated by intra-
venous inoculation of B. henselae and were infested on a
regular basis with fleas in order to mimic the natural transmis-
sion pattern. This group of inoculated cats was housed in a pen
Fig. 1 Bartonella henselae PCR,
culture, and antibody assay results
in six control cats. Gray shaded
areas indicate PCR-positive
samples, and the dotted areas
indicate culture-positive samples.
Titers of IgG are also indicated
1048 Parasitol Res (2015) 114:1045–1050
next to pens with either treated or untreated cats. The pens
were separated from each other by a mesh, preventing cats in
different groups from licking or scratching each other,
yet allowing fleas to infest animals in neighboring pens. In
the different pens, carpets allowed fleas to complete their life
cycle.
In the Bradburry and Lappin (2010) study, the cats in
the B. henselae-infected group became bacteremic within
21 days after intravenous inoculation. The untreated con-
trol cats became bacteremic within 42 to 70 days after
the first flea infestation and had on average less than 6
fleas. The Lappin et al. (2013) study was a long-term
study, and cats were examined for 252 days after the
application of the collar in the treated group. The inocu-
lated cats became bacteremic within 39 days after intra-
venous injection of B. henselae and were infested with
100 C. felis on day 0 and then monthly afterwards. The
mean flea counts on infected and control cats were very
low: <2 in the control group and <8 in the infected
group. Bacteremia and seroconversion were detected in
only four out of seven cats in the control group, while
the treated group remained negative, suggesting an over-
all low infection pressure.
The challenge model used in the present study is based on
direct infestation of cats with B. henselae-infected fleas and
provides several advantages: the amount of fleas used for
infestation is standardized and does not depend on the migra-
tion of fleas from one group of cats to the other. As such, each
cat is equally challenged at the same time, and the challenge
model provides a consistent and high infection pressure.
In the abovementioned studies (Bradbury and Lappin
2010; Lappin et al. 2013), the migration of fleas between the
different groups was generally low, suggesting an inconsistent
infection pressure. Moreover, the fleas detected on the cats
could have originated from adults newly emerged from the
environment. These young fleas are potentially not infected
with B. henselae as the transmission does not seem to occur
transovarially in the flea (Bouhsira et al. 2013a) and as they
did not yet feed on the inoculated cats.
Furthermore, the use of bacteremic cats as infection source
for B. henselae leads to inconsistency in the infection pressure,
as the bacteremia in cats varies in function of the individual
cat, the Bartonella strain, and the route of inoculation
(Kordick and Breitschwerdt 1997; Bradbury and Lappin
2010; Lappin et al. 201). After an intradermal inoculation,
cats became bacteremic within 12 days (unpublished data),
whereas after an intravenous inoculation, cats became bacter-
emic within 21 to 39 days (Bradbury and Lappin 2010;
Lappin et al. 2013).
The use of an artificial feeding system to infect the fleas in
the new challenge model allowed the infection of fleas within
24 h only, synchronizing the start of the exposure to
B. henselae in this study. Furthermore, the infection status of
the fleas can be confirmed on a pool of fleas prior to the
infestation of the cats, either by PCR or indirectly on the
excreted feces by quantitative PCR (Bouhsira et al. 2013b).
In this study, all flea pools used for infestation were confirmed
to be positive for B. henselae.
In the previously used model, the transmission of infection
to other cats is prone to variation, as the fleas placed on the
inoculated cats have to (1) acquire the bacteria from the
inoculated cats and (2) to infest another host before being able
to transmit the infection. Bradburry and Lappin (2010) ob-
tained bacteremia in the control cats within 42 to 70 days with
seroconversion occurring between 63 and 84 days. In the
Lappin (2013) study, not all cats became bacteremic and those
that did occurred within 28 to 140 days. Cats seroconverted
within 56 to 154 days. In the present study using direct
infestation of the cats with infected fleas, bacteremia occurred
in 100 % of the cats within 14 to 41 days, and all cats
seroconverted within 21 to 44 days. These results are in
accordance with previous studies in which SPF kittens were
infested with fleas harvested from contaminated cats (Chomel
et al. 1996).
The use of bacteremic cats as the source of B. henselae can
be questioned in a long-term study, as it is uncertain if cats
remain bacteremic throughout the study. In the Bradburry and
Lappin (2010) study, the inoculated cats were not bacteremic
anymore by day 84, and in the Lappin et al. (2013) study, only
one control cat was bacteremic by that time, and all cats were
negative by day 252, making it impossible to truly evaluate
the efficacy of the ectoparasiticide.
This new challenge model allows regular infestations of
cats with a standardized number of B. henselae-infected fleas.
This challenge model has an additional benefit as it decreases
the number of animals included as contaminated cats are not
used as source of bacteria. The demonstration of an
ectoparasiticidal product efficacy can therefore be performed
using two groups of cats, as in the present study.
In this study, all untreated cats were successfully infected
with B. henselae after infestation with infected fleas. In con-
trast, none of the selamectin-treated cats became positive
during the study, even under the high and continuous infection
pressure of the new challenge model. The high efficacy of
selamectin in the current challenge model is due to the high
efficacy of the product against adult fleas (McTier et al. 2000;
Dryden et al. 2005), larvae, and eggs (Shanks et al. 2000).
The new challenge model confirmed that Stronghold® spot
on is highly efficacious in preventing the transmission of
B. henselae by fleas to cats, under high infection pressure.
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